EcoDrugPlus

Oxytocin Receptor

Ensembl ID : ENSCAFG00020009232
Gene Symbol: OXTR
3 Cross references
265 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSCAFG00020016214
Gene Symbol: PAK4
3 Cross references
160 Possible Orthologues:

Pancreatic Alpha-Amylase

Ensembl ID : ENSCAFG00020011297
Gene Symbol: LOC112640762
2 Cross references
207 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSCAFG00020013630
Gene Symbol: PNLIP
3 Cross references
301 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSCAFG00020014014
Gene Symbol: PTH1R
3 Cross references
199 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSCAFG00020009327
Gene Symbol: PPARA
3 Cross references
455 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSCAFG00020007019
Gene Symbol: PPARD
3 Cross references
420 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSCAFG00020007261
Gene Symbol: PPARG
3 Cross references
406 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSCAFG00020023109
Gene Symbol: PIK3CA
3 Cross references
274 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSCAFG00020008199
Gene Symbol: PIK3CB
3 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSCAFG00020007028
Gene Symbol: PIK3CD
3 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSCAFG00020023105
Gene Symbol: PIK3CG
3 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).